Response by Jia Et Al to Letter Regarding Article, “Interleukin-35 Promotes Macrophage Survival and Improves Wound Healing after Myocardial Infarction in Mice”
Daile Jia,Aijun Sun,Junbo Ge
DOI: https://doi.org/10.1161/circresaha.119.316522
IF: 23.213
2020-01-01
Circulation Research
Abstract:HomeCirculation ResearchVol. 126, No. 4Response by Jia et al to Letter Regarding Article, “Interleukin-35 Promotes Macrophage Survival and Improves Wound Healing After Myocardial Infarction in Mice” Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBResponse by Jia et al to Letter Regarding Article, “Interleukin-35 Promotes Macrophage Survival and Improves Wound Healing After Myocardial Infarction in Mice” Daile Jia, Aijun Sun and Junbo Ge Daile JiaDaile Jia From the Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China (D.J., A.S., J.G.) Shanghai Institute of Cardiovascular Diseases, China (D.J., A.S., J.G.). Search for more papers by this author , Aijun SunAijun Sun From the Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China (D.J., A.S., J.G.) Shanghai Institute of Cardiovascular Diseases, China (D.J., A.S., J.G.). Search for more papers by this author and Junbo GeJunbo Ge https://orcid.org/0000-0002-9360-7332 From the Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China (D.J., A.S., J.G.) Shanghai Institute of Cardiovascular Diseases, China (D.J., A.S., J.G.). Search for more papers by this author Originally published13 Feb 2020https://doi.org/10.1161/CIRCRESAHA.119.316522Circulation Research. 2020;126:e12–e13In Response:We appreciate the comments by Belmadani et al on our recent publication.1 Cytokines of the IL (interleukin)-12 family, comprising IL-12, IL-23, IL-27, and IL-35, are important regulators in cardiovascular diseases.2 All members of the IL-12 cytokine family are dimeric proteins and consist of an alpha subunit (p19, p28, or p35) and a beta-subunit (EBI3 or p40).3 IL-35 subunits (EBI3 and p35) were upregulated in mice after myocardial infarction (MI). After IL-35 inhibition, mice showed impaired infarct healing and worse cardiac function compared with wild-type MI mice.EBI3 associates as a heterodimer with either IL-12p35 or an IL-12p35 homologue, p28, to form cytokines IL-35 and IL-27. Initially, EBI3 knockout mice were used to explore the function of IL-35 in MI. Surprisingly, EBI3 deficiency did not have an overt effect on cardiac function, cardiac remodeling, or survival rate after MI (unpublished data). The phenotype of EBI3 knockout mice may be milder than anticipated owing to the contrasting activities of IL-35 and IL-274 or the changes in pairing and secretion of other subunits.3 Thus, we took advantage of a unique EBI3 monoclonal antibody (mAb) that neutralizes IL-35 but not IL-27, the other known EBI3-containing cytokine.5,6 We agree that the kinetics of the expression and combination of IL-27 subunits (EBI3 and p28) and IL-12 subunits (p35 and p40) in mouse heart tissue at different time points post-MI and their potential role need further exploration. In line with the findings of Vignali,6 we demonstrated IL-27 bioassay was not significantly altered in the presence of anti-IL-35 mAb (unpublished data). However, IL-12 consists of p40 and p35 subunits and is, therefore, unlikely to be neutralized by EBI3 mAb. In our study, the EBI3 neutralizing antibody was administered to p35- or EBI3-deficient mice since EBI3 associates as a heterodimer with IL-12p35 to form IL-35. p35- or EBI3-deficient mice lack IL-35 and thus could abolish the effect of IL-35 neutralization. A previous study showed that disrupting the p35 subunit protected the heart against MI and improved cardiac function7; these effects appear to be divergent from our finding. IL-12p35 is a known subunit of IL-12 and IL-35. IL-12p35 deficiency results in a lack of both IL-12 and IL-35 and might affect other subunits such as p40-p19 and EBI3-p28 pairing and secretion.3 The phenotype of IL-12p35 deficiency might thus be a consequence of multiple factors. Therefore, disrupting the p35 subunit might result in multiple effects, while our results only describe the function of targeting IL-35 alone. The potential interpretation for the cardioprotective effect of IL-12 inhibition against MI in p40-deficient mice might be multiple in that the p40 chain can pair with p35 or p19 to form IL-12 or IL-23, respectively. In addition to function as heterodimers, the p40 subunit can also function as homodimers. p40-deficient mice lack IL-12, IL-23, and p40 homodimers, which greatly complicates data interpretation. Regarding the effects of potentiation of IL-35, we showed that the increased level of IL-35 by administration of mouse recombinant IL-35 reduced cardiac rupture, promoted wound healing and orchestrateed the myocardial inflammatory response after MI (Figures 7 and 8).IL-35 was originally identified in Tregs. The expression of IL-35 in the infarcted tissue is consistent with kinetics of Tregs: increased gradually, peaked on day 7, and returned to baseline level by the second-week post-MI.8 In patients with acute coronary syndromes, peripheral numbers of Tregs are reduced and their functional properties compromised, possibly leading to decreased secretion of IL-35.9 In our study, we tried to measure serum IL-35. IL-35 levels in mouse serum are extremely low and out of the detection range of enzyme-linked immunosorbent assays (unpublished data); hence, we did not present the serum IL-35 data in our article.Chain sharing is a key feature of the IL-12 family of cytokines. Their molecular complexities are the substantial obstacles needing to be overcome. The generation of conditional knockout mice that lack a single, functional cytokine in a specific cell and organ would be promising option for detailed in vivo analysis of cardiovascular diseases. Likewise, because of the chain-sharing propensity of IL-12 family and the unstable nature of IL-27 and IL-35, which lack disulfide linkage, the development of neutralizing monoclonal antibodies with increased specificity and enzyme-linked immunosorbent assays with improved sensitivity is both challenging and highly anticipated. We agree with the comments by Belmadani et al that researchers should explore the complex mechanisms of the IL-12 family and the potential interactions within this family. Indeed, we are now exploring the specific functions of IL-12, IL-27, and IL-35 in cardiovascular diseases using conditional knockout mice, such as p35Flox/Flox, EBI3Flox/Flox 5, and p28 Flox/Flox10 mice.Sources of FundingThis work was supported by a grant of Innovative Research Groups of the National Natural Science Foundation of China (81521001), a grant to Aijun Sun from the National Science Fund for Distinguished Young Scholars (81725002), the National Natural Science Foundation of China (81570224), and the Major Research Plan of the National Natural Science Foundation of China (91639104).DisclosuresNone.FootnotesFor Sources of Funding and Disclosures, see page e13.References1. Jia D, Jiang H, Weng X, Wu J, Bai P, Yang W, Wang Z, Hu K, Sun A, Ge J. Interleukin-35 promotes macrophage survival and improves wound healing after myocardial infarction in mice.Circ Res. 2019; 124:1323–1336. doi: 10.1161/CIRCRESAHA.118.314569LinkGoogle Scholar2. van der Heijden T, Bot I, Kuiper J. The IL-12 cytokine family in cardiovascular diseases.Cytokine. 2019; 122:154188. doi: 10.1016/j.cyto.2017.10.010CrossrefMedlineGoogle Scholar3. Vignali DA, Kuchroo VK. IL-12 family cytokines: immunological playmakers.Nat Immunol. 2012; 13:722–728. doi: 10.1038/ni.2366CrossrefMedlineGoogle Scholar4. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, Cross R, Sehy D, Blumberg RS, Vignali DA. The inhibitory cytokine IL-35 contributes to regulatory T-cell function.Nature. 2007; 450:566–569. doi: 10.1038/nature06306CrossrefMedlineGoogle Scholar5. Turnis ME, Sawant DV, Szymczak-Workman AL, Andrews LP, Delgoffe GM, Yano H, Beres AJ, Vogel P, Workman CJ, Vignali DA. Interleukin-35 limits anti-tumor immunity.Immunity. 2016; 44:316–329. doi: 10.1016/j.immuni.2016.01.013CrossrefMedlineGoogle Scholar6. Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, Finkelstein D, Forbes K, Workman CJ, Brown SA, et al. IL-35-mediated induction of a potent regulatory T cell population.Nat Immunol. 2010; 11:1093–1101. doi: 10.1038/ni.1952CrossrefMedlineGoogle Scholar7. Kan X, Wu Y, Ma Y, Zhang C, Li P, Wu L, Zhang S, Li Y, Du J. Deficiency of IL-12p35 improves cardiac repair after myocardial infarction by promoting angiogenesis.Cardiovasc Res. 2016; 109:249–259. doi: 10.1093/cvr/cvv255CrossrefMedlineGoogle Scholar8. Yan X, Anzai A, Katsumata Y, Matsuhashi T, Ito K, Endo J, Yamamoto T, Takeshima A, Shinmura K, Shen W, et al. Temporal dynamics of cardiac immune cell accumulation following acute myocardial infarction.J Mol Cell Cardiol. 2013; 62:24–35. doi: 10.1016/j.yjmcc.2013.04.023CrossrefMedlineGoogle Scholar9. Mor A, Luboshits G, Planer D, Keren G, George J. Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes.Eur Heart J. 2006; 27:2530–2537. doi: 10.1093/eurheartj/ehl222CrossrefMedlineGoogle Scholar10. Zhang S, Liang R, Luo W, Liu C, Wu X, Gao Y, Hao J, Cao G, Chen X, Wei J, et al. High susceptibility to liver injury in IL-27 p28 conditional knockout mice involves intrinsic interferon-γ dysregulation of CD4+ T cells.Hepatology. 2013; 57:1620–1631. doi: 10.1002/hep.26166CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetails February 14, 2020Vol 126, Issue 4 Advertisement Article InformationMetrics © 2020 American Heart Association, Inc.https://doi.org/10.1161/CIRCRESAHA.119.316522PMID: 32078453 Originally publishedFebruary 13, 2020 PDF download Advertisement SubjectsCoronary Artery DiseaseMyocardial Infarction